“…A plethora of ICD studies have been conducted in many parts of the world examining disclosure of HC in company annual reports (Abeysekera & Guthrie, 2005;April, Bosma & Deglon, 2003;Arvidsson, 2003;Bergamini & Zambon, 2002;Bozzolan, Favotto & Ricceri, 2003;Brennan, 2001;Carnaghan, 1999;Firer & Williams, 2005;Flöstrand & Ström, 2006;Goh & Lim, 2004;Guthrie, Petty, Ferrier & Wells, 1999;Olsson, 2001;Petty & Cuganesan, 2005;Vandemaele, Vergauwen & Smits, 2005;Williams, 2001), IPO prospectuses (Bukh, Nielsen, Gormsen & Mouritsen, 2005;Nielsen et al, 2005), presentations to analysts García-Meca, Parra, Larrán & Martínez, 2005) and sell-side analysts reports (Arvidsson, 2003;Flöstrand, 2006;Flöstrand & Ström, 2006;García-Meca, 2005;Nielsen, 2004). In addition to HCD studies (Hedlin & Adolphson, 2000;Olsson, 2004;Subbarao & Zeghal, 1997), research on ICD in company annual reports and IPO prospectuses have evaluated the level of emphasis placed on HC disclosures by preparers of financial statements.…”